Key Highlights

  • Mercer International (NASDAQ:MERC) rose 90.87% to USD 0.2405 after a planned prepackaged Chapter 11.
  • Karyopharm Therapeutics (NASDAQ:KPTI) fell 7.14% to USD 0.1040 a day after a Chapter 11 filing.
  • Rising Dragon Acquisition (NASDAQ:RDAC) jumped 101.37% to USD 10.27 after its Merger was terminated.
  • Senti Biosciences (NASDAQ:SNTI) dropped 16.06% to USD 0.1578 after a merger left holders with contingent value rights.
  • RedCloud Holdings (NASDAQ:RCT) slid 14.81% to USD 0.0299 while appealing a delisting determination.

Mercer International (NASDAQ:MERC) (up USD 0.1145, 90.87%): Shares Surge on a Planned Prepackaged Chapter 11

In pre-market trading on November 3, 2026, Mercer International (NASDAQ:MERC) rose 90.87% to USD 0.2405. The implied prior close is about USD 0.126 (calculated), so this Penny Stock remains deeply depressed. A November 2, 2026 announcement laid out a Recapitalization that would exchange about USD 1.1 billion of senior notes for equity.

Current common shares would be cancelled, leaving holders with about 8.5% of the new common stock. Mercer missed its October 1, 2026 interest payment on the 2028 notes, and management expects Nasdaq to delist the shares. Third quarter results come after the close on November 5, 2026.

Karyopharm Therapeutics (NASDAQ:KPTI) (down USD 0.0080, 7.14%): Continued Decline Following a Chapter 11 Filing

Karyopharm Therapeutics (NASDAQ:KPTI) slid 7.14% to USD 0.1040 in pre-market trading on November 3, 2026, which implies a Monday close of roughly USD 0.1120 (calculated). The company filed voluntary Chapter 11 petitions on November 2, 2026, and signed a Restructuring Support Agreement calling for a merger with Ayrmid Ltd.

Existing lenders pledged up to USD 55 million of debtor-in-possession financing, subject to court approval. The plan gives common stockholders no distribution, and the company expects existing Equity to be worth nothing. An expected Nasdaq delisting was cited, although none had been confirmed in the filing. Fiscal 2025 net loss was USD 196.0 million.

Rising Dragon Acquisition (NASDAQ:RDAC) (up USD 5.17, 101.37%): Shares Double After a Merger Ends

Rising Dragon Acquisition (NASDAQ:RDAC) climbed 101.37% to USD 10.27 in pre-market trading on November 3, 2026, from an implied prior close of about USD 5.10 (calculated). A November 3, 2026 release announced the mutual termination of its merger agreement with HZJL Cayman Limited, with no termination fee owed. The company did not explain why the shares more than doubled after news that a deal had fallen through.

The release gave no reason for the termination and did not describe the trust account. The company will continue seeking another Business combination. As a blank check company, it faces risks tied to extensions, redemptions and possible liquidation.

Senti Biosciences (NASDAQ:SNTI) (down USD 0.0302, 16.06%): Declining After a Milestone-Only Merger

Senti Biosciences (NASDAQ:SNTI) dropped 16.06% to USD 0.1578 in pre-market trading on November 3, 2026. No company announcement dated November 2 or November 3 was identified. The merger closed on October 21, 2026, and common stockholders received no cash.

Each share receives one contingent value right, with aggregate milestone payments capped at USD 60 million. About USD 16 million of convertible notes were swapped for common stock at USD 0.342 per share. At the screen price, shares trade about 53.9% below that price (calculated). The filing warned operating funds may fall short, and dilution risk is high for this penny stock.

RedCloud Holdings (NASDAQ:RCT) (down USD 0.0052, 14.81%): Sub-Penny Shares Await a Panel Ruling

RedCloud Holdings (NASDAQ:RCT) fell 14.81% to USD 0.0299 in pre-market trading on November 3, 2026. No company announcement dated November 2 or November 3, 2026 was identified. Nasdaq issued a Staff Delisting Determination on October 13, 2026, and the company has appealed, a step that keeps the shares trading.

Shareholders approved a share consolidation, amended at the meeting from 20 for one to 100 for one, although the filing does not confirm the final ratio or an effective date. Reported cash was about USD 767 thousand against a stockholders' Deficit of about USD 20.6 million. This penny stock brings high volatility.

The Bigger Picture

All five stocks face Balance Sheet strain, but their paths differ. Mercer and Karyopharm are using Chapter 11, Rising Dragon is reshaping its plans after a termination, Senti holders own milestone rights, and RedCloud is contesting a delisting decision. Readers should watch the Mercer results on November 5, 2026, court approval of Karyopharm's financing, the Rising Dragon Form 8-K, and the RedCloud Hearings Panel decision. Extended-hours quotes can differ widely from regular-session trades.